Atropine and Demerol

Atropine Sulfate:

• Atropine and Demerol (Atropine Sulfate) reviews

Indication: For the treatment of poisoning by susceptible organophosphorous nerve agents having cholinesterase activity as well as organophosphorous or carbamate insecticides.

Atropine and Demerol (Atropine Sulfate), a naturally occurring belladonna alkaloid, is a racemic mixture of equal parts of d- and l-hyoscyamine, whose activity is due almost entirely to the levo isomer of the drug. Atropine and Demerol (Atropine Sulfate) is commonly classified as an anticholinergic or antiparasympathetic (parasympatholytic) drug. More precisely, however, it is termed an antimuscarinic agent since it antagonizes the muscarine-like actions of acetylcholine and other choline esters. Adequate doses of Atropine and Demerol (Atropine Sulfate) abolish various types of reflex vagal cardiac slowing or asystole. The drug also prevents or abolishes bradycardia or asystole produced by injection of choline esters, anticholinesterase agents or other parasympathomimetic drugs, and cardiac arrest produced by stimulation of the vagus. Atropine and Demerol (Atropine Sulfate) may also lessen the degree of partial heart block when vagal activity is an etiologic factor. Atropine and Demerol (Atropine Sulfate) in clinical doses counteracts the peripheral dilatation and abrupt decrease in blood pressure produced by choline esters. However, when given by itself, Atropine and Demerol (Atropine Sulfate) does not exert a striking or uniform effect on blood vessels or blood pressure.

Meperidine Hydrochloride:

• Indications and usage
• Contraindications
• Warnings
• Precautions
• Adverse reactions
• Drug abuse and addiction
• Overdosage
• Dosage and administration
• Safety and handling
• How supplied
• Meperidine hcl 50mg (cii) tablet
• Atropine and Demerol (Meperidine Hydrochloride) reviews

INDICATIONS AND USAGE

Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets are indicated for the relief of moderate to severe pain.

CONTRAINDICATIONS

Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets are contraindicated in patients with hypersensitivity to Atropine and Demerol (Meperidine Hydrochloride) or to any of its ingredients.

Atropine and Demerol (Meperidine Hydrochloride) is contraindicated in patients who are receiving monoamine oxidase (MAO) inhibitors or those who have recently received such agents. Therapeutic doses of Atropine and Demerol (Meperidine Hydrochloride) have occasionally precipitated unpredictable, severe, and occasionally fatal reactions in patients who have received such agents within 14 days. The mechanism of these reactions is unclear, but may be related to a preexisting hyperphenylalaninemia. Some have been characterized by coma, severe respiratory depression, cyanosis, and hypotension, and have resembled the syndrome of acute narcotic overdose. Serotonin syndrome with agitation, hyperthermia, diarrhea, tachycardia, sweating, tremors and impaired consciousness may also occur. In other reactions the predominant manifestations have been hyperexcitability, convulsions, tachycardia, hyperpyrexia, and hypertension. Although it is not known that other narcotics are free of the risk of such reactions, virtually all of the reported reactions have occurred with Atropine and Demerol (Meperidine Hydrochloride). If a narcotic is needed in such patients, a sensitivity test should be performed in which repeated, small, incremental doses of morphine are administered over the course of several hours while the patient's condition and vital signs are under careful observation. (Intravenous hydrocortisone or prednisolone have been used to treat severe reactions, with the addition of intravenous chlorpromazine in those cases exhibiting hypertension and hyperpyrexia. The usefulness and safety of narcotic antagonists in the treatment of these reactions is unknown.)

Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets are contraindicated in patients with severe respiratory insufficiency (see WARNINGS: Respiratory Conditions ).

WARNINGS

Atropine and Demerol should not be used for treatment of chronic pain. Atropine and Demerol (Meperidine Hydrochloride) should only be used in the treatment of acute episodes of moderate to severe pain. Prolonged Atropine and Demerol (Meperidine Hydrochloride) use may increase the risk of toxicity (e.g., seizures) from the accumulation of the Atropine and Demerol (Meperidine Hydrochloride) metabolite, normeperidine.

Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets are opioid agonists and a Schedule II controlled substance with an abuse liability similar to morphine.

Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

Misuse, Abuse, and Diversion of Opioids

Atropine and Demerol (Meperidine Hydrochloride) is an opioid agonist of the morphine-type. Such drugs are sought by drug abusers and people with addiction disorders and are subject to criminal diversion.

Atropine and Demerol (Meperidine Hydrochloride) can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets have been reported as being abused by crushing, chewing, snorting, or injecting the dissolved product. These practices will result in the uncontrolled delivery of the opioid and pose a significant risk to the abuser that could result in overdose or death (see WARNINGS and DRUG ABUSE AND ADDICTION ).

Concerns about abuse, addiction, and diversion should not prevent the proper management of pain.

Healthcare professionals should contact their State Professional Licensing Board or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.

Interactions with Alcohol and Drugs of Abuse

Atropine and Demerol may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system depression.

Head Injury and Increased Intracranial Pressure

The respiratory depressant effects of Atropine and Demerol (Meperidine Hydrochloride) and its capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a preexisting increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries. In such patients, Atropine and Demerol (Meperidine Hydrochloride) must be used with extreme caution and only if its use is deemed essential.

Respiratory Conditions

Atropine and Demerol should be used with extreme caution in patients having an acute asthmatic attack, patients with chronic obstructive pulmonary disease or cor pulmonale, patients having a substantially decreased respiratory reserve, and patients with preexisting respiratory depression, hypoxia, or hypercapnia. In such patients, even usual therapeutic doses of narcotics may decrease respiratory drive while simultaneously increasing airway resistance to the point of apnea.

Hypotensive Effect

The administration of Atropine and Demerol (Meperidine Hydrochloride) may result in severe hypotension in the postoperative patient or any individual whose ability to maintain blood pressure has been compromised by a depleted blood volume or the administration of drugs such as the phenothiazines or certain anesthetics.

Usage in Ambulatory Patients

Atropine and Demerol may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient should be cautioned accordingly.

Atropine and Demerol (Meperidine Hydrochloride), like other narcotics, may produce orthostatic hypotension in ambulatory patients.

Usage in Pregnancy

Atropine and Demerol (Meperidine Hydrochloride) should not be used in pregnant women prior to the labor period, unless in the judgment of the physician the potential benefits outweigh the possible risks, because safe use in pregnancy prior to labor has not been established relative to possible adverse effects on fetal development.

Labor and Delivery

Atropine and Demerol crosses the placental barrier and can produce depression of respiration and psychophysiologic functions in the newborn. Resuscitation may be required (see OVERDOSAGE ). Therefore Atropine and Demerol (Meperidine Hydrochloride) is not recommended during labor.

Nursing Mothers

Atropine and Demerol (Meperidine Hydrochloride) appears in the milk of nursing mothers receiving the drug. Due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential benefits of the drug to the nursing woman.

PRECAUTIONS

General

Opioid analgesics can have a narrow therapeutic index in certain patient populations, particularly when combined with CNS depressant drugs. The use of these products should be reserved for cases where the benefits of opioid analgesia outweigh the known risks of respiratory depression, altered mental state, and postural hypotension.

Use of Atropine and Demerol hydrochloride tablets may be associated with increased potential risks and should be used with caution in the following conditions: sickle cell anemia, pheochromocytoma, acute alcoholism; adrenocortical insufficiency (e.g., Addison's disease); CNS depression or coma; delirium tremens; debilitated patients; kyphoscoliosis associated with respiratory depression; myxedema or hypothyroidism; prostatic hypertrophy or urethral stricture; severe impairment of hepatic, pulmonary, or renal function; and toxic psychosis (see PRECAUTIONS: Special Risk Patients ).

The administration of Atropine and Demerol (Meperidine Hydrochloride) may obscure the diagnosis or clinical course in patients with acute abdominal conditions. All opioids may induce or aggravate seizures in some clinical settings.

Interactions with Other CNS Depressants

Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets should be used with caution and consideration should be given to starting with a reduced dosage in patients who are concurrently receiving other central nervous system depressants including sedatives or hypnotics, general anesthetics, phenothiazines, other tranquilizers, and alcohol. Drug-drug interactions may result in respiratory depression, hypotension, profound sedation, coma, or death if these drugs are taken in combination with the usual doses of Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets.

Interactions with Mixed Agonist/Antagonist Opioid Analgesics

Agonist/antagonist analgesics should be administered with caution to a patient who has received or is receiving a course of therapy with a pure opioid agonist analgesic such as Atropine and Demerol (Meperidine Hydrochloride). In this situation, mixed agonist/antagonist analgesics may reduce the analgesic effect of Atropine and Demerol (Meperidine Hydrochloride) and/or may precipitate withdrawal symptoms in these patients due to competitive blocking of receptors.

Supraventricular Tachycardias

Atropine and Demerol (Meperidine Hydrochloride) should be used with caution in patients with atrial flutter and other supraventricular tachycardias because of a possible vagolytic action which may produce a significant increase in the ventricular response rate.

Convulsions

Atropine and Demerol may aggravate preexisting convulsions in patients with convulsive disorders. If dosage is escalated substantially above recommended levels because of tolerance development, convulsions may occur in individuals without a history of convulsive disorders.

Acute Abdominal Conditions

The administration of Atropine and Demerol (Meperidine Hydrochloride) or other narcotics may obscure the diagnosis or clinical course in patients with acute abdominal conditions.

Tolerance and Physical Dependence

Atropine and Demerol has the potential to produce tolerance and drug dependence. Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Physical dependence is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical dependence and tolerance are not unusual during chronic opioid therapy.

The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, mydriasis. Other symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.

In general, opioids used regularly should not be abruptly discontinued.

Use in Drug and Alcohol Addiction

Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets are opioids with no approved use in the management of addictive disorders. Its proper usage in individuals with drug or alcohol dependence, either active or in remission, is for the management of pain requiring opioid analgesia. Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets should be used with caution in patients with alcoholism and other drug dependencies due to the increased frequency of narcotic tolerance, dependence, and the risk of addiction observed in these patient populations. Abuse of Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets in combination with other CNS depressant drugs can result in serious risk to the patient.

Information for Patients/Caregivers

If clinically advisable, patients receiving Atropine and Demerol hydrochloride tablets or their caregivers should be given the following information by the physician, nurse, pharmacist, or caregiver:

• Patients should be aware that Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets contain Atropine and Demerol (Meperidine Hydrochloride), which is a morphine-like substance.
• Patients should be advised to report pain and adverse experiences occurring during therapy. Individualization of dosage is essential to make optimal use of this medication.
• Patients should be advised not to adjust the dose of Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets without consulting the prescribing professional.
• Patients should be advised that Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating heavy machinery).
• Patients should not combine Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets with alcohol or other central nervous system depressants (sleep aids, tranquilizers) except by the orders of the prescribing physician, because dangerous additive effects may occur, resulting in serious injury or death.
• Women of childbearing potential who become, or are planning to become pregnant should be advised to consult their physician regarding the effects of analgesics and other drug use during pregnancy on themselves and their unborn child.
• Patients should be advised that Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets are a potential drug of abuse. They should protect them from theft, and they should never be given to anyone other than the individual for whom they were prescribed.
• Patients should be advised that if they have been receiving treatment with Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets for more than a few weeks and cessation of therapy is indicated, it may be appropriate to taper the Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets dose, rather than abruptly discontinue it, due to the risk of precipitating withdrawal symptoms. Their physician can provide a dose schedule to accomplish a gradual discontinuation of the medication.
• Patients should be instructed to keep Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets in a secure place out of the reach of children. When Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets are no longer needed, the unused tablets should be destroyed by flushing down the toilet.

Drug Interactions

Also see WARNINGS .

Acyclovir

Plasma concentrations of Atropine and Demerol and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.

Cimetidine

Cimetidine reduced the clearance and volume of distribution of Atropine and Demerol (Meperidine Hydrochloride) and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.

CNS Depressants

Concomitant use of CNS depressants with usual doses of meperidine may result in respiratory depression, hypotension, profound sedation, coma or death.

Phenytoin

The hepatic metabolism of Atropine and Demerol (Meperidine Hydrochloride) may be enhanced by phenytoin. Concomitant administration resulted in reduced half-life and bioavailability with increased clearance of Atropine and Demerol (Meperidine Hydrochloride) in healthy subjects, however, blood concentrations of normeperidine were increased, thus exercise caution when phenytoin is used concomitantly with Atropine and Demerol (Meperidine Hydrochloride).

Ritonavir

Plasma concentrations of the active metabolite normeperidine may be increased by ritonavir, thus concomitant administration should be avoided.

Opioid analgesics, including Atropine and Demerol hydrochloride tablets, may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.

Special Risk Patients

Atropine and Demerol (Meperidine Hydrochloride) should be given with caution and the initial dose should be reduced in certain patients such as the elderly or debilitated, and those with severe impairment of hepatic or renal function, Sickle Cell Anemia, hypothyroidism, Addison's disease, Pheochromocytoma and prostatic hypertrophy or urethral stricture. In patients with pheochromocytoma, Atropine and Demerol (Meperidine Hydrochloride) has been reported to provoke hypertension.

Usage in Hepatically Impaired Patients

Accumulation of Atropine and Demerol and/or its active metabolite, normeperidine, can occur in patients with hepatic impairment. Atropine and Demerol (Meperidine Hydrochloride) should therefore be used with caution in patients with hepatic impairment.

Usage in Renally Impaired Patients

Accumulation of Atropine and Demerol (Meperidine Hydrochloride) and/or its active metabolite, normeperidine, can also occur in patients with renal impairment. Atropine and Demerol (Meperidine Hydrochloride) should therefore be used with caution in patients with renal impairment.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies to assess the carcinogenic or mutagenic potential of Atropine and Demerol have not been conducted. Studies to determine the effect of Atropine and Demerol (Meperidine Hydrochloride) on fertility have not been conducted.

Pregnancy

Teratogenic Effects

Pregnancy Category C:

Animal reproduction studies have not been conducted with Atropine and Demerol. It is also not known whether Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets should be given to a pregnant woman only if clearly needed.

Labor and Delivery

See WARNINGS .

Nursing Mothers

See WARNINGS .

Pediatric Use

The safety and effectiveness of Atropine and Demerol in pediatric patients has not been established. Literature reports indicate that Atropine and Demerol (Meperidine Hydrochloride) has a slower elimination rate in neonates and young infants compared to older children and adults. Neonates and young infants may also be more susceptible to the effects, especially the respiratory depressant effects. If Atropine and Demerol (Meperidine Hydrochloride) use is contemplated in neonates or young infants, any potential benefits of the drug need to be weighed against the relative risk of the patient.

Geriatric Use

Clinical studies of Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets during product development did not include sufficient numbers of subjects aged 65 and over to evaluate age-related differences in safety or efficacy. Literature reports indicate that geriatric patients have a slower elimination rate compared to young patients and they may be more susceptible to the effects of Atropine and Demerol (Meperidine Hydrochloride). Reducing the total daily dose of meperidine is recommended in elderly patients and the potential benefits of the drug should be weighed against the relative risk to a geriatric patient.

ADVERSE REACTIONS

The major hazards of Atropine and Demerol (Meperidine Hydrochloride), as with other narcotic analgesics, are respiratory depression and, to a lesser degree, circulatory depression; respiratory arrest, shock, and cardiac arrest have occurred.

The most frequently observed adverse reactions include lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. These effects seem to be more prominent in ambulatory patients and in those who are not experiencing severe pain. In such individuals, lower doses are advisable. Some adverse reactions in ambulatory patients may be alleviated if the patient lies down.

Other adverse reactions include:

Nervous System: Mood changes (e.g., euphoria, dysphoria), weakness, headache, agitation, tremor, involuntary muscle movements (e.g., muscle twitches, myoclonus), severe convulsions, transient hallucinations and disorientation, confusion, delirium, visual disturbances.

Gastrointestinal: Dry mouth, constipation, biliary tract spasm.

Cardiovascular: Flushing of the face, tachycardia, bradycardia, palpitation, hypotension (see WARNINGS ), syncope.

Genitourinary: Urinary retention.

Allergic: Pruritus, urticaria, other skin rashes, wheal and flare over the vein with intravenous injection. Hypersensitivity reactions, anaphylaxis.

Histamine release leading to hypotension and/or tachycardia, flushing, sweating, and pruritus.

DRUG ABUSE AND ADDICTION

Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets contain Atropine and Demerol (Meperidine Hydrochloride), a mu-agonist opioid with an abuse liability similar to morphine and is a Schedule II controlled substance. Atropine and Demerol (Meperidine Hydrochloride), like morphine and other opioids used in analgesia, can be abused and is subject to criminal diversion.

Drug addiction is characterized by compulsive use, use for non-medical purposes, and continued use despite harm or risk of harm. Drug addiction is a treatable disease, utilizing a multi-disciplinary approach, but relapse is common.

"Drug seeking" behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated "loss" of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). "Doctor shopping" to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction.

Abuse and addiction are separate and distinct from physical dependence and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets, like other opioids, have been diverted for non-medical use. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.

Abuse of Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets poses a risk of overdose and death. This risk is increased with concurrent abuse of Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets with alcohol and other substances. Due to the presence of talc as one of the excipients in tablets, parenteral abuse of crushed tablets can be expected to result in local tissue necrosis, infection, pulmonary granulomas, and increased risk of endocarditis and valvular heart disease. In addition, parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.

Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

OVERDOSAGE

Symptoms

Serious overdosage with Atropine and Demerol is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, hypothermia, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, particularly by the intravenous route, apnea, circulatory collapse, cardiac arrest, and death may occur.

Treatment

Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. The narcotic antagonist, naloxone hydrochloride, is a specific antidote against respiratory depression which may result from overdosage or unusual sensitivity to narcotics, including Atropine and Demerol (Meperidine Hydrochloride). Therefore, an appropriate dose of this antagonist should be administered as necessary, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation.

An antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular depression.

Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated.

In cases of overdosage with Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets, the stomach should be evacuated by emesis or gastric lavage.

NOTE: In an individual physically dependent on narcotics, the administration of the usual dose of a narcotic antagonist will precipitate an acute withdrawal syndrome. The severity of this syndrome will depend on the degree of physical dependence and the dose of antagonist administered. The use of narcotic antagonists in such individuals should be avoided if possible. If a narcotic antagonist must be used to treat serious respiratory depression in the physically dependent patient, the antagonist should be administered with extreme care and only one-fifth to one-tenth the usual initial dose administered.

DOSAGE AND ADMINISTRATION

For Relief of Pain

Dosage should be adjusted according to the severity of the pain and the response of the patient. Atropine and Demerol is less effective orally than on parenteral administration. The dose of Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets should be proportionately reduced (usually by 25 to 50 percent) when administered concomitantly with phenothiazines and many other tranquilizers since they potentiate the action of Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets.

Adults

The usual dosage is 50 mg to 150 mg orally, every 3 or 4 hours as necessary.

Pediatric Patients

The usual dosage is 1.1 mg/kg to 1.8 mg/kg orally, up to the adult dose, every 3 or 4 hours as necessary (see PRECAUTIONS: Pediatric Use ).

SAFETY AND HANDLING

Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets are a dosage form that contains Atropine and Demerol (Meperidine Hydrochloride) hydrochloride which is a controlled substance. Like morphine, Atropine and Demerol (Meperidine Hydrochloride) is controlled under Schedule II of the Controlled Substances Act. Atropine and Demerol (Meperidine Hydrochloride), like all opioids, is liable to diversion and misuse and should be handled accordingly. Patients and their families should be instructed to flush any Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets that are no longer needed.

Atropine and Demerol (Meperidine Hydrochloride) hydrochloride tablets have been targeted for theft and diversion by criminals. Healthcare professionals should contact their State Professional Licensing Board or State Controlled Substance Authority for information on how to prevent and detect abuse or diversion of this product.

HOW SUPPLIED

Product: 63629-4549

NDC: 63629-4549-1 30 TABLET in a BOTTLE

NDC: 63629-4549-2 50 TABLET in a BOTTLE

NDC: 63629-4549-3 60 TABLET in a BOTTLE

NDC: 63629-4549-4 90 TABLET in a BOTTLE

NDC: 63629-4549-5 120 TABLET in a BOTTLE

Manufactured for:

QUALITEST PHARMACEUTICALS

Huntsville, AL 35811

8181647

Rev 12/11

R7

Atropine and Demerol HCL 50mg (CII) Tablet